China NMPA Inspection - Guangxi Beilunhe Medical Industry Group Co., Ltd. - July 28, 2016

On April 12, 2016, an inspection team conducted an on-site verification at Guangxi Beilunhe Medical Industry Group Co., Ltd., following the company's submission of a "Production Suspension Report" to the Guangxi Zhuang Autonomous Region Food and Drug Administration. The purpose of this verification was to confirm the company's operational status, which was indeed found to be in a state of production suspension. This engagement falls under the regulatory oversight of the Guangxi Zhuang Autonomous Region Food and Drug Administration, highlighting a structured framework for managing manufacturing activities within the region. While no specific violations were cited in relation to the suspension itself, the document outlines a critical procedural requirement for the company's future operations. To resume production, Guangxi Beilunhe Medical Industry Group Co., Ltd. is mandated to submit a formal written report to the Guangxi Zhuang Autonomous Region Food and Drug Administration. This report must demonstrate the company's readiness and adherence to all relevant regulations. Crucially, production can only recommence after the administration has thoroughly reviewed the submitted report, conducted its own verification processes, and officially confirmed that all regulatory requirements have been fully satisfied. This ensures that any resumption of manufacturing aligns with established safety and quality standards, safeguarding public health and maintaining regulatory compliance within the medical industry.